Previous close | 224.30 |
Open | 226.10 |
Bid | 220.20 x N/A |
Ask | 231.40 x N/A |
Day's range | 222.50 - 228.00 |
52-week range | 212.30 - 298.40 |
Volume | |
Avg. volume | 917,021 |
Market cap | 191.607B |
Beta (5Y monthly) | 0.18 |
PE ratio (TTM) | 17.37 |
EPS (TTM) | 13.00 |
Earnings date | 25 Jul 2024 |
Forward dividend & yield | 9.50 (3.99%) |
Ex-dividend date | 16 Mar 2023 |
1y target est | N/A |
More than half of all U.S. cervical cancer patients are underscreened1, which makes reducing barriers to sample collection and increasing access to screenings crucial to ultimately helping eliminate this deadly disease.Each year in the U.S., more than 13,000 patients are diagnosed with cervical cancer and approximately 4,000 die from this preventable disease, caused by HPV infection.1Roche’s human papillomavirus (HPV) self-collection solution will improve access to testing by providing women the
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript May 7, 2024 Halozyme Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. My name is [Perla] (ph), and I’ll be your conference operator today. […]
Q1 2024 Halozyme Therapeutics Inc Earnings Call